UnitedHealth Group (UNH) was riding high near $620 earlier this year, touted as one of the strongest recession proof stocks you could own. Today it trades near $308, a drop that has shocked many investors and traders alike. The steep decline follows a series of earnings misses, weakening profit margins, and management turmoil that shook confidence in the company’s outlook.
Revenue for 2025 is still expected to grow about 13% year over year, reaching roughly $112 billion. But net income took a hard hit, down nearly 36% in the first quarter. Free cash flow also shrank close to 20%, signaling that growth is not translating into cash like it used to. Earnings per share estimates have been slashed to about $24.70 for the year, down from earlier forecasts near $30.
Bullish case
• UnitedHealth’s massive scale and diversified services provide a strong operational foundation
• Analysts maintain a moderate buy rating with average price targets around $415, implying about 34% upside
• Recent CEO transition could stabilize leadership and restore confidence
• Healthcare remains a defensive sector amid market volatility
Bearish case
• Earnings deterioration points to margin pressure in Medicare Advantage and other segments
• Management changes and regulatory inquiries increase uncertainty
• Political risks around healthcare policy continue to loom
• Valuations may decline further if earnings guidance remains weak
Social media chatter reflects mixed emotions. Traders on Reddit and Twitter express frustration with many calling it a “dip turned trap.” Option traders are playing defense, with put-call ratios rising above 0.9, signaling increased hedging activity.
Technically, the stock found short-term support near $292, holding steady through recent dips. A break below that could see prices fall to $269. Resistance lies at $325, with $365 next if momentum recovers. Active traders might consider range plays between $292 and $325 while awaiting clearer earnings direction.
The setup looks complicated. Structural headwinds create downside risk, but liquidity and size offer a potential bounce. Buying near $292 might be a trade for those who believe the worst is priced in, but caution remains necessary given margin pressures and political risks.
Disclaimer: this is not financial advice